Overview

Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Status:
Enrolling by invitation

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

This is a phase I/II randomized, masked, clinical trial to determine the safety and efficacy of intravitreal administration of cerliponase alfa.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

David L Rogers, MD